Retinopathy of prematurity is a leading cause of childhood blindness worldwide and is treated based on the presence of symptoms of “plus disease,” a dilation and tortuosity of retinal vessels. This pr
Background: Combined treatment with BRAF -V600 and MEK inhibitors has significantly improved progression-free and overall survival of patients with BRAF -mutated melanoma. Pa
Pathological neovascularization (NV) can cause visual impairment in retinopathy of prematurity (ROP). Current treatments addressing vasoproliferative (Phase II) ROP are costly and can lead to severe c
